Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetic Risk Factors for Osteonecrosis of the Hip Among Children With Leukemia

30 Sept 2004

Abstract excerpt

PURPOSE: One of the adverse effects of therapy for acute lymphoblastic leukemia (ALL) is osteonecrosis of the hip. Putative risk factors for osteonecrosis have included being female, white race, and older age. Our goal was to define possible genetic risk factors for osteonecrosis among children treated for newly diagnosed ALL. METHODS: Using a candidate gene approach, we determined the genotypes for 16 common...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone and Joint Diseases
Share to Bone health and treatments
Share to Hip disorders and treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 15459215
DOI: 10.1200/jco.2004.11.020

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic Risk Factors for Osteonecrosis of the Hip Among Children With LeukemiaPMID 15459215Read ↗

Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia.Semantic proximity Read ↗

A thymidylate synthase polymorphism is associated with increased risk for bone toxicity among children treated for acute lymphoblastic leukemia.Semantic proximity Read ↗

Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia.Semantic proximity Read ↗

Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia.Semantic proximity Read ↗

Genetic Biomarkers to Identify the Risk of Osteonecrosis in Children with Acute Lymphoblastic Leukemia.Semantic proximity Read ↗

ALL and osteonecrosis.Semantic proximity Read ↗

A GRIN3A polymorphism may be associated with glucocorticoid-induced symptomatic osteonecrosis in children with acute lymphoblastic leukemia.Semantic proximity Read ↗

Comparing osteonecrosis clinical phenotype, timing, and risk factors in children and young adults treated for acute lymphoblastic leukemia.Semantic proximity Read ↗

Genetic factors contributing to late adverse musculoskeletal effects in childhood acute lymphoblastic leukemia survivors.Semantic proximity Read ↗

Genetic Determinants of Treatment-Related Bone Toxicity in Pediatric Acute Lymphoblastic Leukemia.Semantic proximity Read ↗

Genetic polymorphism of vitamin D receptors and plasminogen activator inhibitor-1 and osteonecrosis risk in childhood acute lymphoblastic leukemia.Semantic proximity Read ↗

Genetic Background of Medication-Related Osteonecrosis of the Jaw: Current Evidence and Future Perspectives.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.